Media stories about ContraFect (NASDAQ:CFRX) have trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ContraFect earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.7046157522384 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of ContraFect (CFRX) traded down $0.01 during trading on Friday, hitting $0.90. The stock had a trading volume of 55,104 shares, compared to its average volume of 86,073. ContraFect has a 12 month low of $0.80 and a 12 month high of $2.50.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-contrafect-cfrx-stock-price/1756079.html.

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Insider Buying and Selling by Quarter for ContraFect (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.